POLG2 Gene Progressive External Ophthalmoplegia with Mitochondrial Deletions Type 4 Autosomal Dominant Genetic Test
Test Name: POLG2 Gene Progressive External Ophthalmoplegia with Mitochondrial Deletions Type 4 Autosomal Dominant Genetic Test
Components: Blood or Extracted DNA or One drop Blood on FTA Card
Price: 4400.0 AED
Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card
Report Delivery: 3 to 4 Weeks
Method: NGS Technology
Test Type: Neurological Disorders
Doctor: Neurologist
Test Department: Genetics
Pre Test Information: Clinical History of Patient who is going for POLG2 Gene Progressive External Ophthalmoplegia with Mitochondrial Deletions Type 4 Autosomal Dominant NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with POLG2 Gene Progressive External Ophthalmoplegia with Mitochondrial Deletions Type 4 Autosomal Dominant.
Test Details
Progressive External Ophthalmoplegia with Mitochondrial Deletions Type 4 Autosomal Dominant (PEOA4) is a genetic disorder that affects the muscles responsible for eye movement. It is caused by mutations in the POLG2 gene.
NGS (Next-Generation Sequencing) Genetic Test is a diagnostic tool used to analyze the DNA sequence of an individual’s genes. It is a high-throughput technology that can simultaneously analyze multiple genes, making it useful for identifying genetic mutations associated with various diseases.
In the case of PEOA4, an NGS Genetic Test can be used to identify mutations in the POLG2 gene. This test involves obtaining a DNA sample, usually through a blood sample, and sequencing the DNA to identify any variations or mutations in the POLG2 gene.
By identifying mutations in the POLG2 gene, healthcare professionals can confirm a diagnosis of PEOA4 and provide appropriate medical management and genetic counseling for affected individuals and their families.
| Test Name | POLG2 Gene Progressive external ophthalmoplegia with mitochondrial deletions type 4 autosomal dominant Genetic Test |
|---|---|
| Components | |
| Price | 4400.0 AED |
| Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card o |
| Report Delivery | 3 to 4 Weeks |
| Method | NGS Technology |
| Test type | Neurological Disorders |
| Doctor | Neurologist |
| Test Department: | Genetics |
| Pre Test Information | Clinical History of Patient who is going for POLG2 Gene Progressive external ophthalmoplegia with mitochondrial deletions type 4, autosomal dominant NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with POLG2 Gene Progressive external ophthalmoplegia with mitochondrial deletions type 4, autosomal dominant |
| Test Details |
Progressive external ophthalmoplegia with mitochondrial deletions type 4, autosomal dominant (PEOA4) is a genetic disorder that affects the muscles responsible for eye movement. It is caused by mutations in the POLG2 gene. NGS (Next-Generation Sequencing) Genetic Test is a diagnostic tool used to analyze the DNA sequence of an individual’s genes. It is a high-throughput technology that can simultaneously analyze multiple genes, making it useful for identifying genetic mutations associated with various diseases. In the case of PEOA4, an NGS Genetic Test can be used to identify mutations in the POLG2 gene. This test involves obtaining a DNA sample, usually through a blood sample, and sequencing the DNA to identify any variations or mutations in the POLG2 gene. By identifying mutations in the POLG2 gene, healthcare professionals can confirm a diagnosis of PEOA4 and provide appropriate medical management and genetic counseling for affected individuals and their families. |
